AudioScholar Hematology Weekly (India)

Editor's Pick: International Cross-Age Consensus Guideline on Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia (Blood, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning T-cell redirection and targeted therapy in B-cell lymphomas, new diagnostic and treatment thinking in bone marrow failure, and efforts to standardize risk assessm… This week's papers: 1. CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study.. Blood Advances 2026. 2. CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia.. Blood 2026. 3. Infectious complications following bispecific antibody or CAR T therapy in adult patients with hematologic malignancies: a retrospective database analysis.. Blood Cancer Journal 2026. 4. Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL.. American Journal of Hematology 2026. 5. Upfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes.. Blood 2026. 6. Salvage therapy for immune-mediated bone marrow failure.. Leukemia 2026. 7. Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasm.. Blood 2026. 8. Pivekimab sunirine and the evolving treatment of blastic plasmacytoid dendritic cell neoplasm.. Blood 2026. 9. International Cross-Age Consensus Guideline on Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia.. Blood 2026. 10. Prospective study of longitudinal geriatric assessment with risk-adapted interventions for older patients in allogeneic hematopoietic cell transplantation.. Haematologica 2026. Listen at https://audioscholar.cc/episode/ucr3d4d3ss

Editor's Pick: Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma (Blood Advances, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning FLT3 biology and biomarkers in acute myeloid leukemia, transplantation and complement-driven disease, and treatment selection in lymphoma. Let's dive in. This week's papers: 1. Quizartinib in older patients (aged ≥60 years) with newly diagnosed FLT3-ITDpositive acute myeloid leukemia: subgroup analyses from QuANTUM-First.. Haematologica 2026. 2. Prognostic Impact of FLT3-ITD Microclones in AML: An EHA AML-Specialized Working Group Study.. American Journal of Hematology 2026. 3. Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the…. British Journal of Haematology 2026. 4. Reduced-Intensity Haploidentical Bone Marrow Transplantation in Children with Severe Sickle Cell Disease: BMT CTN 1507.. Blood Advances 2026. 5. Fludarabine-treosulfan compared with fludarabine-melphalan conditioning for adult acute lymphoblastic leukemia.. Blood Advances 2026. 6. Low Incidence of Cryptic Genetic Marrow Failure in Pediatric Severe Aplastic Anemia Following Negative Clinical Workup.. Blood 2026. 7. Efficacy and Safety of NTQ5082 in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria.. American Journal of Hematology 2026. 8. Patterns of Response to Eculizumab in High-Risk Transplant-Associated Thrombotic Microangiopathy.. Blood Advances 2026. 9. Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma.. Blood Advances 2026. 10. Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL.. Blood Advances 2026. Listen at https://audioscholar.cc/episode/brygb5taj4

Editor's Pick: Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial (The Lancet, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning new oral and targeted therapies in non-malignant hematology, a fresh look at treatment strategy in the myeloproliferative neoplasms, and the risks that come with… This week's papers: 1. Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.. The Lancet 2026. 2. Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.. American Journal of Hematology 2026. 3. Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study.. Journal of Thrombosis and Haemostasis 2026. 4. Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy.. Journal of Thrombosis and Haemostasis 2026. 5. Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.. Blood Cancer Journal 2026. 6. High Initial Dose and Accelerated vs. Slow Titration Ropeginterferon Alfa-2b for Polycythemia Vera: A Meta-Analysis.. Blood Advances 2026. 7. New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.. American Journal of Hematology 2026. 8. Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis.. Blood Advances 2026. 9. Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers.. Blood 2026. 10. Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis.. British Journal of Haematology 2026. Listen at https://audioscholar.cc/episode/fnu3j7zm6j

Editor's Pick: Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning chemotherapy-free and residual-disease-guided approaches in acute leukemia, a fresh look at myeloproliferative neoplasms, and the promise and pitfalls of curative… This week's papers: 1. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.. New England Journal of Medicine 2026. 2. Flow MRD pre-blinatumomab consolidation, despite subsequent clearance, is associated with inferior survival in Ph+ B-ALL.. Blood Advances 2026. 3. A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.. Blood 2026. 4. American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults.. Blood Advances 2026. 5. Incidence of thrombosis and bleeding in patients with JAK2- positive myeloproliferative neoplasms receiving low-dose aspirin: a systematic review and meta-anal…. Journal of Thrombosis and Haemostasis 2026. 6. National Alliance of Sickle Cell Disease Consensus Recommendations for Gene Therapy Implementation.. Blood Advances 2026. 7. Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease-modifying therapy.. British Journal of Haematology 2026. 8. Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A.. Blood 2026. 9. Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation.. Blood Advances 2026. 10. Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.. Nature Medicine 2026. Listen at https://audioscholar.cc/episode/jemyngahqs

Editor's Pick: Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry (Leukemia, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning frontline therapy and response endpoints in myeloid disease, the shifting landscape of allogeneic transplantation, and new evidence in myeloma and lymphoma care. This week's papers: 1. Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA…. Leukemia 2026. 2. Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients tr…. Leukemia 2026. 3. Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for…. Haematologica 2026. 4. Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.. Blood Advances 2026. 5. Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.. Blood 2026. 6. Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.. Blood 2026. 7. Allogeneic stem cell transplantation in aggressive Adult T cell leukemia/lymphoma: a prospective multicenter study.. Blood Advances 2026. 8. MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.. Leukemia 2026. 9. Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy.. American Journal of Hematology 2026. 10. Molecular surveillance of aggressive large B-cell lymphoma using circulating tumor DNA duplexes.. Haematologica 2026. Listen at https://audioscholar.cc/episode/e6j7mbj2m8

Editor's Pick: First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival (Leukemia, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning bispecific antibodies moving into older and frailer patients, the fixed-duration versus continuous therapy debate in chronic lymphocytic leukemia, and genomic too… This week's papers: 1. Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.. Blood 2026. 2. A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.. Blood 2026. 3. Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study.. Blood Cancer Journal 2026. 4. First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.. Leukemia 2026. 5. Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era.. Blood 2026. 6. Functional Classification of Monoallelic TP53 Mutations Refines Prognostic Stratification in Myelodysplastic Neoplasms.. Blood 2026. 7. Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.. Blood 2026. 8. Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.. Blood 2026. 9. Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.. Blood 2026. 10. New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT.. Blood 2026. Listen at https://audioscholar.cc/episode/w9dskk3y5j

Editor's Pick: Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma (British Journal of Haematology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning lymphoid malignancy therapy and prognostication, thrombosis and antibody-mediated coagulopathy, and a new generation of prediction tools built on ordinary blood t… This week's papers: 1. Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.. Blood 2026. 2. Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.. British Journal of Haematology 2026. 3. A randomized phase 2 placebo-controlled trial of clobetasol solution for oral chronic graft-versus-host disease therapy.. Blood Advances 2026. 4. SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.. British Journal of Haematology 2026. 5. Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s).. Leukemia 2026. 6. Teclistamab for the treatment of autoantibody-mediated coagulation disorders.. Journal of Thrombosis and Haemostasis 2026. 7. Endotheliopathy and VWF-ADAMTS13 axis dysfunction in VEXAS thrombogenicity.. Blood 2026. 8. Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests.. British Journal of Haematology 2026. 9. Intravenous Immunoglobulin (IVIG) use in HIT and efficacy of early IVIG compared to standard of care treatment.. Journal of Thrombosis and Haemostasis 2026. 10. Machine learning models for suspected pulmonary embolism in emergency department patients: a multicentre diagnostic study.. Thrombosis and Haemostasis 2026. Listen at https://audioscholar.cc/episode/su8nhxcdf5

Editor's Pick: Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia (Blood, 2026) Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning acute leukaemia therapy and risk stratification, maintenance strategies and prognostic modelling in myeloma and CLL, and a pair of practical updates in thrombosis… This week's papers: 1. Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia.. Blood 2026. 2. Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-St…. American Journal of Hematology 2026. 3. How I Treat: MRD testing to personalize allogeneic HCT for adults with AML.. Blood 2026. 4. Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of…. British Journal of Haematology 2026. 5. Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multi…. British Journal of Haematology 2026. 6. Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma.. Blood 2026. 7. Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities.. British Journal of Haematology 2026. 8. Perioperative Management of Patients on Factor XI or Factor XIa Inhibitors.. Journal of Thrombosis and Haemostasis 2026. 9. Diagnosis and management of subsegmental pulmonary embolism.. Journal of Thrombosis and Haemostasis 2026. 10. mRNA-encoding CD19-targeting T cell engager for refractory immune thrombocytopenia.. Cell 2026. Listen at https://audioscholar.cc/episode/fxg5embgm5

Editor's Pick: Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (The Lancet, 2026) Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning inherited red cell disorders and the anaemias, immune-based therapies moving earlier into plasma cell and acute leukaemia, and protein replacement strategies in b… This week's papers: 1. Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, p…. The Lancet 2026. 2. Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial.. Blood 2026. 3. Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.. Nature Medicine 2026. 4. Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline.. Annals of Internal Medicine 2026. 5. FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors.. Journal of Thrombosis and Haemostasis 2026. 6. Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.. American Journal of Hematology 2026. 7. Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemi…. British Journal of Haematology 2026. 8. Sickle cell anaemia with and without crises: An observational study of pregnancy outcomes.. British Journal of Haematology 2026. 9. Stroke incidence and phenotype in Saudi patients with sickle cell disease: A longitudinal cohort study.. British Journal of Haematology 2026. 10. Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.. Leukemia 2026. Listen at https://audioscholar.cc/episode/qfusf38ayt

Editor's Pick: Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium (British Journal of Haematology, 2026) Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning risk stratification across myeloid and plasma cell disorders, salvage and supportive strategies in acute leukaemia and bone marrow failure, and a set of papers th… This week's papers: 1. Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A r…. British Journal of Haematology 2026. 2. How I Treat Pediatric Hematology-Oncology Patients from Families Identifying as Jehovah's Witnesses.. Blood 2026. 3. Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex : A Prospective Cohort Study.. Annals of Internal Medicine 2026. 4. Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.. Leukemia 2026. 5. Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.. British Journal of Haematology 2026. 6. Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.. Leukemia 2026. 7. Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis.. Blood Advances 2026. 8. Age- and sex-adjusted genomic differences between Korean and Beat AML cohorts.. Blood Advances 2026. 9. Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults.. British Journal of Haematology 2026. 10. ADAMTS13 fusion constructs with dual activity against VWF: a novel strategy for iTTP.. Journal of Thrombosis and Haemostasis 2026. Listen at https://audioscholar.cc/episode/h6bwhua35f